1.	Hormone Therapy in Treating Men With Stage IV Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: Adult Sponsor: NCI, Other Protocol IDs: CDR0000064184, SWOG-9346, CAN-NCIC-PR8, CALGB-9594, ECOG-S9346, EORTC-30985, CAN-NCIC-JPR8, INT-0162, PR8, NCT00002651
2.	Trial to Evaluate Radiotherapy Followed by Endocrine Therapy Vs Endocrine Therapy Alone for PSA Failure After Radical Prostatectomy Phase: Phase III Type: Treatment Status: Active Age: 20 to 79 Sponsor: Other Protocol IDs: JCOG0401, C000000026, NCT00138008
3.	Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS) Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: CDR0000571528, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
4.	Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000577574, RTOG-0534, NCT00567580
5.	Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000648194, RTOG-0815, NCT00936390
6.	Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000701128, RTOG-0924, NCT01368588
7.	S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: S1216, U10CA032102, NCI-2012-02876, NCT01809691
8.	Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NYU 08-479, NCT00878436
9.	Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: DUT112661, Health Canada-112661, NCT00866554
10.	Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02648, E2809, CDR0000689613, ECOG-E2809, U10CA021115, NCT01251861
11.	A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9785-CL-0222, 2010-021868-15, NCT01288911
12.	Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16684, NCT01531205
13.	TAK-700 in Castration Resistant Prostate Cancer Phase: Phase II Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: EORTC-1211, 2012-002122-67, NCT01658527
14.	Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MDV3100-09, NCT01664923
15.	Degarelix Neo-Adjuvant Radical Prostatectomy Trial Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: DEG_PRE-OP_001, Degarelix Pre-Op, NCT01674270
16.	Everolimus, Bicalutamide, and Leuprolide Acetate in Treating Patients Undergoing Radiation Therapy For High-Risk Locally Advanced Prostate Cancer Phase: Phase I Type: Treatment Status: Active Age: Under 80 Sponsor: Other Protocol IDs: CDR0000639358, CLCC-RHOMUS, CRAD001 C2486, INCA-RECF0921, EUDRACT-2007-003620-38, RHOMUS, NCT00943956
17.	Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11D.243, 2011-32, NCT01420250
18.	Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2011.008, HUM00047650, NCT01642732
19.	Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer Phase: No phase specified Type: Treatment Status: Active Age: 70 and over Sponsor: Other Protocol IDs: 10-625-A, NCT01342367